New Wound Treatment Contains Antimicrobial Silver in an Amorphous Gel

The SilvaSorb antimicrobial gel provides a quick and easy way to protect burns, cuts, scrapes, and other wounds from infection. SilvaSorb utilizes a proprietary formulation that combines silver with additional compounds that provide for a targeted release of antimicrobial silver for up to seven days without harming healthy tissue; when applied immediately, the SilvaSorb gel has been shown to be effective against Methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant organisms. The Silvasorb gel is available in three different forms:

Wound dressings that combine a proprietary microlattice technology with a stabilized, controlled-release formulation of infection-fighting ionic silver. Due to its unique ability to regulate moisture at the wound site, the SilvaSorb dressings help to sustain an optimal healing environment while providing added broad-spectrum antimicrobial protection against infections.

Cavity dressings that are used for treating tunneling, undermined, or heavily draining partial or full thickness wounds. The SilvaSorb cavity dressings combine SilvaSorb technology with microlattice in a filamented configuration, providing for a seven-day antimicrobial barrier to control heavy drainage or to fill wound cavities.

Site dressings that provide up to a seven-day antimicrobial barrier and are specially designed for use around the percutaneous entry or insertion sites of indwelling lines such as central lines, intravenous (IV) sets, or protruding orthopedic appliances. The SilvaSorb gel products are a product of AcryMed (Beaverton, OR, USA), a fully owned subsidiary of I-Flow Corporation (Lake Forest, CA, USA), and have been approved by the U.S. Food and Drug Administration (FDA) for both over-the-counter and prescription-only marketing and distribution.

"Our new stabilized silver antimicrobial wound gel is yet another unique and unrivaled product that we are proud to add to our growing portfolio of infection-reducing products," said Donald Earhart, I-Flow's chairman and CEO. "I-Flow is already a leader in improving clinical and economic outcomes when treating pain following surgery and continues to develop innovative products that improve patient outcomes."

Related Links:
AcryMed
I-Flow Corporation